Trials / Completed
CompletedNCT04592315
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients Without Prior Antiviral Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected individuals without prior antiviral treatment, and to investigate the pharmacokinetic characteristics of infected patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lipovirtide Injection | Single dosage of Lipovirtide Injection |
Timeline
- Start date
- 2021-01-23
- Primary completion
- 2023-05-02
- Completion
- 2023-07-11
- First posted
- 2020-10-19
- Last updated
- 2026-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04592315. Inclusion in this directory is not an endorsement.